3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
27
Neoplasms
3
Neoplasm Metastasis
3
Metastatic Castration-Resistant Prostate Cancer
3
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bites and Stings
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Carboplatin
5
Radiotherapy
4
Radiation
3
Radiotherapy, Conformal
2
Platinum
2
Pemetrexed
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Disulfides
2
Cisplatin
2
Bevacizumab
2
1,2-diaminocyclohexaneplatinum II citrate
2
veliparib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
methoxyamine
1
lazertinib
1
durvalumab
1
capmatinib
1
Taxes
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Nivolumab
1
Metformin
1
Ipilimumab
1
Granulocyte Colony-Stimulating Factor
1
Gefitinib
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
enzalutamide
×
30 days
×
Clear all
No trials found.